ABAndreas Brieke

Andreas Brieke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andreas Brieke has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Enhanced Thrombin Formation in Patients With Ventricular Assist Devices Experiencing Bleeding: Insights From the Multicenter PREVENT Study

    by Walter Jeske, John Ransom, Jason N. Katz, Ahmet Kilic, Joann Lindenfeld, Gregory Egnaczyk, Palak Shah, Andreas Brieke, Nir Uriel, Daniel Crandall, et al.

    The aim of this investigation was to characterize the hemostatic status of heart failure patients with implanted left ventricular assist devices (LVADs) to propose a mechanism associated with bleeding. Patients (n = 300) from 23 US hospitals were enrolled in the PREVENtion of HeartMate II Pump Thrombosis through Clinical Management (PREVENT) study. A biobank was established with serum and plasma samples prospectively collected from a cohort of 175 patients preimplant baseline (BL) and 3 months (3M) postimplant. Outcomes were collected for 6 months. Thrombin (prothrombin fragment 1.2 [F1.2], functional thrombin generation [TG]) and fibrinolytic activity (D-dimer, plasminogen activator inhibitor-1 [PAI-1]), but not contact activation (complement C5a), were elevated in heart failure patients at BL. F1.2, TG, and PAI-1 levels decreased 3M after LVAD implantation (p < 0.01) but did not revert to normal in all patients; conversely, D-dimer increased BL to 3M (p < 0.01). Compared with patients without events, thrombin activity (F1.2) was increased in patients with late bleeding (3–4 months postimplant) (p = 0.06) and in those with late gastrointestinal (GI) bleeding (p = 0.01). Patients with 3M F1.2 levels above the cohort mean had a higher incidence of bleeding (p < 0.001) and GI bleeding (p < 0.001) compared with those with below mean F1.2. Patients experiencing multiple bleeding events were more likely to have 3M F1.2 greater than the cohort mean. Despite anticoagulation with aspirin and warfarin, LVAD implanted patients exhibit hemostatic activation. Excess thrombin formation, particularly shown by increased F1.2, was demonstrated in association with bleeding in LVAD implanted patients.


  • Proteomic Profiles Of Left Ventricular Assist Device Implantation

    by Daniel H. Katz, Ginger Jiang, Laurie A. Farrell, Dongxiao Shen, Christina Aquilante, Andreas Brieke, JoAnn Lindenfeld, Pablo Andres Quintero Pinzon, Marwa A. Sabe, Robert E. Gerszten

  • Variability in Blood Pressure Assessment in Patients Supported with the HeartMate 3TM

    by Jennifer A. Cowger, Jerry D. Estep, Debbie A. Rinde-Hoffman, Michael M. Givertz, Allen S. Anderson, Daniel Jacoby, Leway Chen, Andreas Brieke, Claudius Mahr, Shelley Hall, et al.

    Targeted blood pressure (BP) control is a goal of left ventricular assist device medical management, but the interpretation of values obtained from noninvasive instruments is challenging. In the MOMENTUM 3 Continued Access Protocol, paired BP values in HeartMate 3 (HM3) patients were compared from arterial (A)-line and Doppler opening pressure (DOP) (319 readings in 261 patients) and A-line and automated cuff (281 readings in 247 patients). Pearson (R) correlations between A-line mean arterial (MAP) and systolic blood pressures (SBP) were compared with DOP and cuff measures according to the presence (>1 pulse in 5 seconds) or absence of a palpable radial pulse. There were only moderate correlations between A-line and noninvasive measurements of SBP (DOP R = 0.58; cuff R = 0.47) and MAP (DOP R = 0.48; cuff R = 0.37). DOP accuracy for MAP estimation, defined as the % of readings within ± 10 mmHg of A-line MAP, decreased from 80% to 33% for DOP ≤ 90 vs. >90 mmHg, and precision also diminished (mean absolute difference [MAD] increased from 6.3 ± 5.6 to 16.1 ± 11.4 mmHg). Across pulse pressures, cuff MAPs were within ±10 mmHg of A-line 62.9%–68.8% of measures and MADs were negligible. The presence of a palpable pulse reduced the accuracy and precision of the DOP-MAP estimation but did not impact cuff-MAP accuracy or precision. In summary, DOP may overestimate MAP in some patients on HM3 support. Simultaneous use of DOP and automated cuff and radial pulse may be needed to guide antihypertensive medication titration in outpatients on HM3 support.


  • DO EARLY CHANGES IN LEFT VENTRICULAR EJECTION FRACTION PREDICT LONG-TERM OUTCOMES AFTER TRANSCATHETER MITRAL VALVE REPAIR OF SECONDARY MITRAL REGURGITATION? THE COAPT TRIAL

    by Stamatios Lerakis, Annapoorna Subhash Kini, Federico M. Asch, Neil J. Weissman, Paul A. Grayburn, Saibal Kar, Kar, Scott Lim, Jacob M. Mishell, Brian Whisenant, et al.

  • Open Access

    HeartMate II System Controller Failure Presenting as Driveline Fault With Repeated Pump Stoppages

    by Kelsey M. Flint, Andreas Brieke, William K. Cornwell, Christopher Pierce, Joseph C. Cleveland, Jay D. Pal